Search

Your search keyword '"Tsukune, Yutaka"' showing total 44 results
Start Over Author "Tsukune, Yutaka"
44 results on '"Tsukune, Yutaka"'

1. Primary analysis of a prospective cohort study of Japanese patients with plasma cell neoplasms in the novel drug era (2016–2021)

Author

Shibayama, Hirohiko, Itagaki, Mitsuhiro, Handa, Hiroshi, Yokoyama, Akihiro, Saito, Akio, Kosugi, Satoru, Ota, Shuichi, Yoshimitsu, Makoto, Tanaka, Yasuhiro, Kurahashi, Shingo, Fuchida, Shin-ichi, Iino, Masaki, Shimizu, Takayuki, Moriuchi, Yukiyoshi, Toyama, Kohtaro, Mitani, Kinuko, Tsukune, Yutaka, Kada, Akiko, Tamura, Hideto, Abe, Masahiro, Iwasaki, Hiromi, Kuroda, Junya, Takamatsu, Hiroyuki, Sunami, Kazutaka, Kizaki, Masahiro, Ishida, Tadao, Saito, Toshiki, Matsumura, Itaru, Akashi, Koichi, and Iida, Shinsuke

Published
2024
Full Text
View/download PDF

3. Circulating cell-free DNA in the peripheral blood plasma of patients is an informative biomarker for multiple myeloma relapse

Author

Yasui, Hiroshi, Kobayashi, Masayuki, Sato, Kota, Kondoh, Kanya, Ishida, Tadao, Kaito, Yuta, Tamura, Hideto, Handa, Hiroshi, Tsukune, Yutaka, Sasaki, Makoto, Komatsu, Norio, Tanaka, Norina, Tanaka, Junji, Kizaki, Masahiro, Kawamata, Toyotaka, Makiyama, Junya, Yokoyama, Kazuaki, Imoto, Seiya, Tojo, Arinobu, and Imai, Yoichi

Published
2021
Full Text
View/download PDF

4. l‐asparaginase monotherapy as an encouraging approach towards acute fulminant chronic active Epstein–Barr virus infection.

Author

Furukawa, Yoshiki, Ando, Jun, Ishii, Midori, Kinoshita, Shintaro, Goto, Ayaka, Tachibana, Kota, Azusawa, Yoko, Kato, Takao, Izumi, Norihide, Hosoya, Erina, Uchimura, Ayana, Inano, Tadaaki, Shirane, Shuichi, Tsukune, Yutaka, Takaku, Tomoiku, Hamano, Yasuharu, and Ando, Miki

Subjects
CORD blood transplantation, HEMATOPOIETIC stem cell transplantation, TRANSPOSITION of great vessels, EPSTEIN-Barr virus diseases, STEM cell transplantation, BRAIN abscess
Abstract

The article discusses the use of l‐asparaginase (l‐Asp) monotherapy in treating acute fulminant chronic active Epstein–Barr virus infection, a life-threatening condition. Two rare cases of patients with high EBV-DNA levels and organ dysfunction were successfully treated with l‐Asp, leading to the initiation of hematopoietic stem cell transplantation (HSCT). The study found that l‐Asp may be an effective bridging therapy to reduce tumor burden before HSCT in such cases, as CAEBV tumor cells have low levels of asparagine synthetase, potentially contributing to the drug's effectiveness. [Extracted from the article]

Published
2024
Full Text
View/download PDF

7. Data from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

Author

Ishibashi, Mariko, primary, Takahashi, Risa, primary, Tsubota, Asako, primary, Sasaki, Makoto, primary, Handa, Hiroshi, primary, Imai, Yoichi, primary, Tanaka, Norina, primary, Tsukune, Yutaka, primary, Tanosaki, Sakae, primary, Ito, Shigeki, primary, Asayama, Toshio, primary, Sunakawa, Mika, primary, Kaito, Yuta, primary, Kuribayashi-Hamada, Yasuko, primary, Onodera, Asaka, primary, Moriya, Keiichi, primary, Komatsu, Norio, primary, Tanaka, Junji, primary, Odajima, Takeshi, primary, Sugimori, Hiroki, primary, Inokuchi, Koiti, primary, and Tamura, Hideto, primary

Published
2023
Full Text
View/download PDF

8. Supplementary Tables S1 to S5 and Supplemental Figures 1 to 15 from SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

Author

Ishibashi, Mariko, primary, Takahashi, Risa, primary, Tsubota, Asako, primary, Sasaki, Makoto, primary, Handa, Hiroshi, primary, Imai, Yoichi, primary, Tanaka, Norina, primary, Tsukune, Yutaka, primary, Tanosaki, Sakae, primary, Ito, Shigeki, primary, Asayama, Toshio, primary, Sunakawa, Mika, primary, Kaito, Yuta, primary, Kuribayashi-Hamada, Yasuko, primary, Onodera, Asaka, primary, Moriya, Keiichi, primary, Komatsu, Norio, primary, Tanaka, Junji, primary, Odajima, Takeshi, primary, Sugimori, Hiroki, primary, Inokuchi, Koiti, primary, and Tamura, Hideto, primary

Published
2023
Full Text
View/download PDF

9. Retrospective analysis of prognostic factors for Waldenstrӧm macroglobulinemia: a multicenter cooperative study in Japan

Author

Saito, Akio, Isoda, Atsushi, Kojima, Masaru, Yokohama, Akihiko, Tsukune, Yutaka, Sasaki, Makoto, Ito, Shigeki, Ohtsu, Akihiro, Koike, Michiaki, Murayama, Kayoko, Moriya, Keiichi, Tamura, Hideto, Matsumoto, Morio, Nakahashi, Hirotaka, Tanosaki, Sakae, Sakura, Tohru, Kawamura, Toshihide, Miyanaga, Tomomi, Nakamura, Naoya, Murakami, Hirokazu, Handa, Hiroshi, and Tsukamoto, Norifumi

Published
2017
Full Text
View/download PDF

12. Incidence and clinical background of hepatitis B virus reactivation in multiple myeloma in novel agents’ era

Author

Tsukune, Yutaka, Sasaki, Makoto, Odajima, Takeshi, Isoda, Atsushi, Matsumoto, Morio, Koike, Michiaki, Tamura, Hideto, Moriya, Keiichi, Ito, Shigeki, Asahi, Maki, Imai, Yoichi, Tanaka, Junji, Handa, Hiroshi, Koiso, Hiromi, Tanosaki, Sakae, Hua, Jian, Hagihara, Masao, Yahata, Yuriko, Suzuki, Satoko, Watanabe, Sumio, Sugimori, Hiroki, and Komatsu, Norio

Published
2016
Full Text
View/download PDF

13. A pilot study examining the efficacy of hochuekkito for improving quality of life in patients with myeloproliferative neoplasms

Author

Edahiro, Yoko, primary, Koike, Michiaki, additional, Nojiri, Shuko, additional, Harada, Yoshinao, additional, Gotoh, Akihiko, additional, Fujibayashi, Kazutoshi, additional, Nishizaki, Yuji, additional, Yanagisawa, Naotake, additional, Takaku, Tomoiku, additional, Nitta, Hideaki, additional, Tsukune, Yutaka, additional, Misawa, Kyohei, additional, Kobayashi, Hiroyuki, additional, and Komatsu, Norio, additional

Published
2022
Full Text
View/download PDF

14. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan

Author

Tsukune, Yutaka, Sasaki, Makoto, Odajima, Takeshi, Sunami, Kazutaka, Takei, Tomomi, Moriuchi, Yukiyoshi, Iino, Masaki, Isoda, Atsushi, Nakaya, Aya, Muta, Tsuyoshi, Miyake, Takaaki, Miyazaki, Koji, Shimizu, Takayuki, Nakajima, Kei, Igarashi, Aiko, Nagafuji, Koji, Kurihara, Taro, Aoyama, Tomonori, Sugimori, Hiroki, and Komatsu, Norio

Published
2017
Full Text
View/download PDF

16. Hodgkin Lymphoma on Hemodialysis Successfully Treated with Extended Courses of Brentuximab Vedotin

Author

Uchimura, Ayana, primary, Yasuda, Hajime, additional, Ando, Jun, additional, Ota, Yasunori, additional, Sasaki, Makoto, additional, Takaku, Tomoiku, additional, Tsukune, Yutaka, additional, Tsutsui, Miyuki, additional, Edahiro, Yoko, additional, Watanabe, Naoki, additional, Ochiai, Tomonori, additional, Komatsu, Norio, additional, and Ando, Miki, additional

Published
2022
Full Text
View/download PDF

18. Improvement in the Symptoms and VEGF Levels after Resection of an Extrame Dullary Spinal Tumor and Additional Chemotherapy in a Patient with Multiple Myeloma Complicated with POEMS Syndrome

Author

Sano, Mariko, primary, Iseki, Tatou, additional, Sasaki, Makoto, additional, Tsukune, Yutaka, additional, Yasuda, Hajime, additional, Kanazawa, Kazo, additional, Arakawa, Atsushi, additional, Yokoyama, Kazumasa, additional, Komatsu, Norio, additional, Hattori, Nobutaka, additional, and Nishioka, Kenya, additional

Published
2021
Full Text
View/download PDF

24. SLAMF3-Mediated Signaling via ERK Pathway Activation Promotes Aggressive Phenotypic Behaviors in Multiple Myeloma

Author

Ishibashi, Mariko, primary, Takahashi, Risa, additional, Tsubota, Asako, additional, Sasaki, Makoto, additional, Handa, Hiroshi, additional, Imai, Yoichi, additional, Tanaka, Norina, additional, Tsukune, Yutaka, additional, Tanosaki, Sakae, additional, Ito, Shigeki, additional, Asayama, Toshio, additional, Sunakawa, Mika, additional, Kaito, Yuta, additional, Kuribayashi-Hamada, Yasuko, additional, Onodera, Asaka, additional, Moriya, Keiichi, additional, Komatsu, Norio, additional, Tanaka, Junji, additional, Odajima, Takeshi, additional, Sugimori, Hiroki, additional, Inokuchi, Koiti, additional, and Tamura, Hideto, additional

Published
2020
Full Text
View/download PDF

30. A New Prognostic Index for Waldenström Macroglobulinemia Based on a Multicenter Retrospective Study of the Japanese Society of Myeloma

Author

Saito, Akio, primary, Isoda, Atsushi, additional, Odajima, Takeshi, additional, Itagaki, Mitsuhiro, additional, Yamamoto, Go, additional, Hagiwara, Shotaro, additional, Ohno, Tatsuharu, additional, Fujimoto, Ayumi, additional, Sekiguchi, Naohiro, additional, Sunami, Kazutaka, additional, Yokohama, Akihiko, additional, Kurokawa, Mineo, additional, Tsukune, Yutaka, additional, Nakazawa, Hideyuki, additional, Takamatsu, Hiroyuki, additional, Yagi, Hideo, additional, Fuchida, Shin-Ichi, additional, Ito, Shigeki, additional, Harazaki, Yoriko, additional, Watanabe, Reiko, additional, Koike, Michiaki, additional, Miyazaki, Kanji, additional, Suzuki, Kazuhito, additional, Tamura, Hideto, additional, Kohara, Takae, additional, Ozaki, Shuji, additional, Nakamura, Nobuhiko, additional, Nakamura, Yuichi, additional, Wakayama, Toshio, additional, Sugimori, Hiroki, additional, and Murakami, Hirokazu, additional

Published
2018
Full Text
View/download PDF

31. Clinical impact of serum soluble SLAMF7 in multiple myeloma

Author

Ishibashi, Mariko, primary, Soeda, Saori, additional, Sasaki, Makoto, additional, Handa, Hiroshi, additional, Imai, Yoichi, additional, Tanaka, Norina, additional, Tanosaki, Sakae, additional, Ito, Shigeki, additional, Odajima, Takeshi, additional, Sugimori, Hiroki, additional, Asayama, Toshio, additional, Sunakawa, Mika, additional, Kaito, Yuta, additional, Kinoshita, Ryosuke, additional, Kuribayashi, Yasuko, additional, Onodera, Asaka, additional, Moriya, Keiichi, additional, Tanaka, Junji, additional, Tsukune, Yutaka, additional, Komatsu, Norio, additional, Inokuchi, Koiti, additional, and Tamura, Hideto, additional

Published
2018
Full Text
View/download PDF

33. Incidence and risk factors of hepatitis B virus reactivation in patients with multiple myeloma in an era with novel agents: a nationwide retrospective study in Japan

Author

Tsukune Yutaka, Sasaki Makoto, Odajima Takeshi, Sunami Kazutaka, Takei Tomomi, Moriuchi Yukiyoshi, Iino Masaki, Isoda Atsushi, Nakaya Aya, Muta Tsuyoshi, Miyake Takaaki, Miyazaki Koji, Shimizu Takayuki, Nakajima Kei, Igarashi Aiko, Nagafuji Koji, Kurihara Taro, Aoyama Tomonori, Sugimori Hiroki, Komatsu Norio, Tsukune Yutaka, Sasaki Makoto, Odajima Takeshi, Sunami Kazutaka, Takei Tomomi, Moriuchi Yukiyoshi, Iino Masaki, Isoda Atsushi, Nakaya Aya, Muta Tsuyoshi, Miyake Takaaki, Miyazaki Koji, Shimizu Takayuki, Nakajima Kei, Igarashi Aiko, Nagafuji Koji, Kurihara Taro, Aoyama Tomonori, Sugimori Hiroki, and Komatsu Norio

Published
2017

35. Retrospective Analysis of Prognostic Factors for Waldenström Macroglobulinemia: A Multicenter Cooperative Study in Japan

Author

Saito, Akio, primary, Isoda, Atsushi, additional, Yokohama, Akihiko, additional, Handa, Hiroshi, additional, Tsukamoto, Norifumi, additional, Tsukune, Yutaka, additional, Sasaki, Makoto, additional, Matsumoto, Morio, additional, Sawamura, Morio, additional, Ito, Shigeki, additional, Toyama, Kohtaro, additional, Koike, Michiaki, additional, Murayama, Kayoko, additional, Onodera, Asaka, additional, Moriya, Keiichi, additional, Tamura, Hideto, additional, Nakahashi, Hirotaka, additional, Tanosaki, Sakae, additional, Sakura, Toru, additional, Karasawa, Masamitsu, additional, Iwashina, Masanori, additional, Kojima, Masaru, additional, Nakamura, Naoya, additional, and Murakami, Hirokazu, additional

Published
2015
Full Text
View/download PDF

37. Zygomycosis

Author

Mori, Takeshi, primary, Yahata, Yuriko, additional, and Tsukune, Yutaka, additional

Published
2011
Full Text
View/download PDF

40. Immune checkpoint molecule DNAM-1/CD112 axis is a novel target for natural killer-cell therapy in acute myeloid leukemia.

Author

Kaito Y, Sugimoto E, Nakamura F, Tsukune Y, Sasaki M, Yui S, Yamaguchi H, Goyama S, Nannya Y, Mitani K, Tamura H, and Imai Y

Subjects
Humans, Nectins, Killer Cells, Natural, Receptors, Immunologic, Cell- and Tissue-Based Therapy, Antigens, Differentiation, T-Lymphocyte genetics, Antigens, Differentiation, T-Lymphocyte metabolism, Immune Checkpoint Proteins metabolism, Leukemia, Myeloid, Acute genetics, Leukemia, Myeloid, Acute therapy, Leukemia, Myeloid, Acute metabolism
Abstract

Acute myeloid leukemia (AML) is a hematologic malignancy that frequently relapses, even if remission can be achieved with intensive chemotherapy. One known relapse mechanism is the escape of leukemic cells from immune surveillance. Currently, there is no effective immunotherapy for AML because of the lack of specific antigens. Here, we aimed to elucidate the association between CD155 and CD112 in AML cell lines and primary AML samples and determine the therapeutic response. Briefly, we generated NK-92 cell lines (NK-92) with modified DNAX-associated molecule 1 (DNAM-1) and T-cell immunoglobulin and ITIM domain (TIGIT), which are receptors of CD155 and CD112, respectively. Analysis of 200 cases of AML indicated that the survival of patients with high expression of CD112 was shorter than that of patients with low expression. NK-92 DNAM-1 exhibited enhanced cytotoxic activity against AML cell lines and primary cells derived from patients with AML. DNAM-1 induction in NK-92 cells enhanced the expression of cytotoxicity-related genes, thus overcoming the inhibitory activity of TIGIT. Between CD155 and CD112, CD112 is an especially important target for natural killer (NK)-cell therapy of AML. Using a xenograft model, we confirmed the enhanced antitumor effect of NK-92 DNAM-1 compared with that of NK-92 alone. We also discovered that CD112 (Nectin-2), an immune checkpoint molecule belonging to the Nectin/Nectin-like family, functions as a novel target of immunotherapy. In conclusion, modification of the DNAM-1/CD112 axis in NK cells may be an effective novel immunotherapy for AML. Furthermore, our findings suggest that the levels of expression of these molecules are potential prognostic markers in AML.

Published
2024
Full Text
View/download PDF

41. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].

Author

Edahiro Y, Gotoh A, Inano T, Tsutsui M, Tsukune Y, Yasuda H, and Komatsu N

Subjects
Aged, Anemia complications, Blood Transfusion, Humans, Male, Primary Myelofibrosis complications, Thalidomide therapeutic use, Anemia drug therapy, Primary Myelofibrosis drug therapy, Thalidomide analogs & derivatives
Abstract

Primary myelofibrosis (PMF) is commonly associated with anemia. IMiD ® immunomodulatory drugs including thalidomide and lenalidomide have been shown to be effective in improving anemia associated with PMF. However, because of adverse events, their use has been restricted. Herein we report the case of a 67-year-old male patient with transfusion-dependent PMF treated with the immunomodulatory drug pomalidomide in a clinical trial. Significant improvements in anemia and thrombocytopenia were observed with pomalidomide, and the patient recovered from transfusion dependence for 8 months. Although phase 3 trial failed to show the superiority of pomalidomide over placebo, pomalidomide may have some benefit in selected patients with transfusion-dependent PMF.

Published
2018
Full Text
View/download PDF

42. [Chronic myeloid leukemia complicated by pulmonary hypertension during dasatinib therapy: a single-center retrospective study].

Author

Edahiro Y, Takaku T, Konishi H, Tsukune Y, Fujioka I, Takasu K, Gotoh A, Daida H, and Komatsu N

Subjects
Aged, Antineoplastic Agents therapeutic use, Dasatinib therapeutic use, Humans, Male, Middle Aged, Retrospective Studies, Antineoplastic Agents adverse effects, Dasatinib adverse effects, Hypertension, Pulmonary chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy
Abstract

Pulmonary artery hypertension (PAH) has been reported to be a severe adverse event associated with dasatinib therapy. Among the 76 chronic myeloid patients who were treated with dasatinib at our hospital, six patients showed high estimated pulmonary arterial systolic pressure, as observed by echocardiography. PAH was confirmed using right heart catheterization in three (3.9%) patients with increased mean pulmonary artery pressure (mPAP). In one patient, although mPAP was higher than the normal range, it did not fulfill the criteria of pulmonary hypertension. After the discontinuation of dasatinib, BNP and dyspnea were improved in five patients. Therefore, it should be noted that dasatinib can cause PAH at higher rates than those reported previously, and if PAH is confirmed or suspected during dasatinib therapy, then dasatinib should be immediately discontinued.

Published
2017
Full Text
View/download PDF

43. Clinical benefits of bortezomib-containing regimens for newly diagnosed AL amyloidosis with severe cardiac impairment.

Author

Tsukune Y, Yahata Y, Sasaki M, Hiki M, Tsutsui M, Hamano Y, Itoh S, Miyazaki T, Dohi T, Maruyama M, Gotoh A, and Komatsu N

Subjects
Aged, Amyloidosis complications, Female, Heart Diseases etiology, Humans, Male, Middle Aged, Treatment Outcome, Amyloidosis drug therapy, Bortezomib therapeutic use, Heart Diseases drug therapy
Abstract

Cardiac amyloid light-chain amyloidosis (AL amyloidosis) is a rare disease with a very poor prognosis, associated with plasma cell dyscrasias such as monoclonal gammopathy of undetermined significance and multiple myeloma. Though bortezomib-containing regimens have achieved high hematologic response rates, there are still few reports describing the outcomes of Japanese patients. Six patients with severe cardiac AL amyloidosis were treated with bortezomib-containing regimens. Involved free light chain (iFLC) decreased immediately in most of these cases. However, the condition of heart failure and N-terminal pro-B-type natriuretic peptide (NT-proBNP) worsened in the early phase of this treatment and then improved several months later. At 29 months, the median duration of follow-up (2-47months), all patients remain alive except one who died of sudden cardiac arrest. Bortezomib-containing regimens are considered to be among the effective treatments for severe cardiac AL amyloidosis.

Published
2016
Full Text
View/download PDF

44. Primary pleural of mucosa-associated lymphoid tissue lymphoma.

Author

Yamada A, Sugimoto K, Matuno K, Tutui M, Yahata Y, Tsukune Y, Koike M, and Komatsu N

Subjects
Aged, Antibodies, Monoclonal, Murine-Derived administration & dosage, Antineoplastic Combined Chemotherapy Protocols administration & dosage, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor analysis, CA-125 Antigen analysis, Cyclophosphamide administration & dosage, Diagnosis, Differential, Doxorubicin administration & dosage, Female, Humans, Lymphoma, B-Cell, Marginal Zone complications, Lymphoma, B-Cell, Marginal Zone drug therapy, Membrane Proteins analysis, Pleural Effusion drug therapy, Pleural Effusion etiology, Pleural Neoplasms complications, Pleural Neoplasms drug therapy, Prednisone administration & dosage, Rituximab, Tomography, X-Ray Computed, Vincristine administration & dosage, Lymphoma, B-Cell, Marginal Zone diagnosis, Pleural Neoplasms diagnosis
Abstract

A 68-year-old female presented with shortness of breath. Chest radiography showed pleural effusion in the right side only. She was suspected of having ovarian cancer because CA125 levels were increased in the pleural effusion, and she consulted our hospital. A chest CT scan showed right pleural nodular lesions. Thoracoscopic pleural resection was performed. Histologic examination of a biopsy specimen showed the diffuse infiltration of small∼medium, mature lymphocytes. These lymphocytes were found to be positive for CD20 and CD79a, but negative for CD3 by immunohistochemistry. These results were interpreted as being consistent with a diagnosis of mucosa-associated lymphoid tissue lymphoma (MALT lymphoma). She commenced chemotherapy with R-CHOP, and the pleural effusion disappeared. MALT lymphoma arising in the pleura is very rare, with only 12 published cases, and most cases have been described in Japan. CA125 levels correlated with the stage, tumor bulk, and presence of effusion. This patient exhibited a high level of CA125 that decreased with therapy.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results